• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Signaling through urokinase and urokinase receptor in lung cancer cells requires interactions with beta1 integrins.肺癌细胞中通过尿激酶和尿激酶受体的信号传导需要与β1整合素相互作用。
J Cell Sci. 2008 Nov 15;121(Pt 22):3747-56. doi: 10.1242/jcs.029769. Epub 2008 Oct 21.
2
Interleukin-1alpha enhances the aggressive behavior of pancreatic cancer cells by regulating the alpha6beta1-integrin and urokinase plasminogen activator receptor expression.白细胞介素-1α通过调节α6β1整合素和尿激酶型纤溶酶原激活剂受体的表达增强胰腺癌细胞的侵袭行为。
BMC Cell Biol. 2006 Feb 20;7:8. doi: 10.1186/1471-2121-7-8.
3
Urokinase-type plasminogen activator receptors associate with beta1 and beta3 integrins of fibrosarcoma cells: dependence on extracellular matrix components.尿激酶型纤溶酶原激活剂受体与纤维肉瘤细胞的β1和β3整合素相关联:对细胞外基质成分的依赖性。
Cancer Res. 1997 May 1;57(9):1682-9.
4
A new class of orthosteric uPAR·uPA small-molecule antagonists are allosteric inhibitors of the uPAR·vitronectin interaction.一类新型的正向变构uPAR·uPA小分子拮抗剂是uPAR·玻连蛋白相互作用的别构抑制剂。
ACS Chem Biol. 2015 Jun 19;10(6):1521-34. doi: 10.1021/cb500832q. Epub 2015 Mar 31.
5
Urokinase receptors promote beta1 integrin function through interactions with integrin alpha3beta1.尿激酶受体通过与整合素α3β1相互作用促进β1整合素功能。
Mol Biol Cell. 2001 Oct;12(10):2975-86. doi: 10.1091/mbc.12.10.2975.
6
RhoB regulates uPAR signalling.RhoB 调控 uPAR 信号。
J Cell Sci. 2012 May 15;125(Pt 10):2369-80. doi: 10.1242/jcs.091579. Epub 2012 Feb 24.
7
Functional relevance of urinary-type plasminogen activator receptor-alpha3beta1 integrin association in proteinase regulatory pathways.尿激酶型纤溶酶原激活物受体-α3β1整合素在蛋白酶调节途径中的功能相关性
J Biol Chem. 2006 May 12;281(19):13021-13029. doi: 10.1074/jbc.M508526200. Epub 2006 Mar 1.
8
ECRG2 regulates cell migration/invasion through urokinase-type plasmin activator receptor (uPAR)/beta1 integrin pathway.ECRG2通过尿激酶型纤溶酶原激活物受体(uPAR)/β1整合素途径调节细胞迁移/侵袭。
J Biol Chem. 2009 Nov 6;284(45):30897-906. doi: 10.1074/jbc.M109.011213. Epub 2009 Aug 28.
9
Urokinase receptors are required for alpha 5 beta 1 integrin-mediated signaling in tumor cells.尿激酶受体是肿瘤细胞中α5β1整合素介导的信号传导所必需的。
J Biol Chem. 2007 Feb 9;282(6):3929-39. doi: 10.1074/jbc.M607989200. Epub 2006 Dec 4.
10
Antagonistic anti-urokinase plasminogen activator receptor (uPAR) antibodies significantly inhibit uPAR-mediated cellular signaling and migration.拮抗型抗尿激酶型纤溶酶原激活物受体 (uPAR) 抗体可显著抑制 uPAR 介导的细胞信号转导和迁移。
J Biol Chem. 2010 Aug 27;285(35):26878-26888. doi: 10.1074/jbc.M109.077677. Epub 2010 May 25.

引用本文的文献

1
N-Glycosylation as a Key Requirement for the Positive Interaction of Integrin and uPAR in Glioblastoma.N-糖基化是胶质母细胞瘤中整合素与尿激酶型纤溶酶原激活物受体正向相互作用的关键要求。
Int J Mol Sci. 2025 May 31;26(11):5310. doi: 10.3390/ijms26115310.
2
Revealing the role of cancer-associated fibroblast senescence in prognosis and immune landscape in pancreatic cancer.揭示癌症相关成纤维细胞衰老在胰腺癌预后和免疫格局中的作用。
iScience. 2024 Dec 16;28(1):111612. doi: 10.1016/j.isci.2024.111612. eCollection 2025 Jan 17.
3
Therapeutic strategies targeting uPAR potentiate anti-PD-1 efficacy in diffuse-type gastric cancer.靶向 uPAR 的治疗策略增强了抗 PD-1 疗效在弥漫型胃癌中的作用。
Sci Adv. 2022 May 27;8(21):eabn3774. doi: 10.1126/sciadv.abn3774. Epub 2022 May 25.
4
Urokinase-type plasminogen activator receptor (uPAR) as a therapeutic target in cancer.尿激酶型纤溶酶原激活物受体(uPAR)作为癌症的治疗靶点。
J Transl Med. 2022 Mar 18;20(1):135. doi: 10.1186/s12967-022-03329-3.
5
HIF-Dependent Activation Upregulates and in Intestinal Epithelium in Inflammatory Bowel Disease.缺氧诱导因子依赖性激活在炎症性肠病中上调并存在于肠道上皮中。
Front Genet. 2021 Nov 11;12:791640. doi: 10.3389/fgene.2021.791640. eCollection 2021.
6
The Urokinase Receptor (uPAR) as a "Trojan Horse" in Targeted Cancer Therapy: Challenges and Opportunities.尿激酶受体(uPAR)作为靶向癌症治疗中的“特洛伊木马”:挑战与机遇
Cancers (Basel). 2021 Oct 27;13(21):5376. doi: 10.3390/cancers13215376.
7
Adipose-PAS interactions in the context of its localised bio-engineering potential (Review).脂肪组织与过碘酸希夫反应在其局部生物工程潜力背景下的相互作用(综述)
Biomed Rep. 2021 Aug;15(2):70. doi: 10.3892/br.2021.1446. Epub 2021 Jul 5.
8
Metalloproteinases in Ovarian Cancer.卵巢癌中的金属蛋白酶。
Int J Mol Sci. 2021 Mar 26;22(7):3403. doi: 10.3390/ijms22073403.
9
Molecular imaging of the urokinase plasminogen activator receptor: opportunities beyond cancer.尿激酶型纤溶酶原激活物受体的分子成像:癌症之外的机遇
EJNMMI Res. 2020 Jul 28;10(1):87. doi: 10.1186/s13550-020-00673-7.
10
uPAR antibody (huATN-658) and Zometa reduce breast cancer growth and skeletal lesions.尿激酶型纤溶酶原激活物受体抗体(huATN - 658)和唑来膦酸可抑制乳腺癌生长并减少骨转移灶。
Bone Res. 2020 Apr 17;8:18. doi: 10.1038/s41413-020-0094-3. eCollection 2020.

本文引用的文献

1
Modification of kidney barrier function by the urokinase receptor.尿激酶受体对肾脏屏障功能的调节
Nat Med. 2008 Jan;14(1):55-63. doi: 10.1038/nm1696. Epub 2007 Dec 16.
2
Kininostatin associates with membrane rafts and inhibits alpha(v)beta3 integrin activation in human umbilical vein endothelial cells.激肽抑制素与膜筏结合并抑制人脐静脉内皮细胞中的α(v)β3整合素激活。
Arterioscler Thromb Vasc Biol. 2007 Sep;27(9):1968-75. doi: 10.1161/ATVBAHA.107.148759. Epub 2007 Jun 21.
3
uPAR-induced cell adhesion and migration: vitronectin provides the key.尿激酶型纤溶酶原激活物受体(uPAR)诱导的细胞黏附和迁移:玻连蛋白起关键作用。
J Cell Biol. 2007 Jun 4;177(5):927-39. doi: 10.1083/jcb.200612058.
4
Tumor microenvironment promotes cancer progression, metastasis, and therapeutic resistance.肿瘤微环境促进癌症进展、转移和治疗抵抗。
Curr Probl Cancer. 2007 Mar-Apr;31(2):36-100. doi: 10.1016/j.currproblcancer.2006.12.002.
5
Proteomic identification of lynchpin urokinase plasminogen activator receptor protein interactions associated with epithelial cancer malignancy.与上皮癌恶性肿瘤相关的关键尿激酶型纤溶酶原激活物受体蛋白相互作用的蛋白质组学鉴定。
J Proteome Res. 2007 Mar;6(3):1016-28. doi: 10.1021/pr060518n.
6
Cancer statistics, 2007.2007年癌症统计数据。
CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66. doi: 10.3322/canjclin.57.1.43.
7
Urokinase plasminogen activator and plasminogen activator inhibitor type-1 in nonsmall-cell lung cancer: relation to prognosis and angiogenesis.非小细胞肺癌中尿激酶型纤溶酶原激活物和1型纤溶酶原激活物抑制剂:与预后和血管生成的关系
Lung Cancer. 2007 Apr;56(1):43-50. doi: 10.1016/j.lungcan.2006.11.018. Epub 2007 Jan 17.
8
Urokinase receptors are required for alpha 5 beta 1 integrin-mediated signaling in tumor cells.尿激酶受体是肿瘤细胞中α5β1整合素介导的信号传导所必需的。
J Biol Chem. 2007 Feb 9;282(6):3929-39. doi: 10.1074/jbc.M607989200. Epub 2006 Dec 4.
9
Activation of urokinase receptor by a novel interaction between the connecting peptide region of urokinase and alpha v beta 5 integrin.通过尿激酶连接肽区域与αvβ5整合素之间的新型相互作用激活尿激酶受体。
J Cell Sci. 2006 Aug 15;119(Pt 16):3424-34. doi: 10.1242/jcs.03067. Epub 2006 Aug 1.
10
Urokinase induces activation of STAT3 in lung epithelial cells.尿激酶可诱导肺上皮细胞中信号转导和转录激活因子3(STAT3)的激活。
Am J Physiol Lung Cell Mol Physiol. 2006 Oct;291(4):L772-80. doi: 10.1152/ajplung.00476.2005. Epub 2006 Jun 2.

肺癌细胞中通过尿激酶和尿激酶受体的信号传导需要与β1整合素相互作用。

Signaling through urokinase and urokinase receptor in lung cancer cells requires interactions with beta1 integrins.

作者信息

Tang Chi-Hui, Hill Marla L, Brumwell Alexis N, Chapman Harold A, Wei Ying

机构信息

Pulmonary and Critical Care Division, Department of Medicine, Cardiovascular Research Institute, University of California San Francisco, San Francisco, CA 94143, USA.

出版信息

J Cell Sci. 2008 Nov 15;121(Pt 22):3747-56. doi: 10.1242/jcs.029769. Epub 2008 Oct 21.

DOI:10.1242/jcs.029769
PMID:18940913
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3903460/
Abstract

The urokinase receptor (uPAR) is upregulated upon tumor cell invasion and correlates with poor lung cancer survival. Although a cis-interaction with integrins has been ascribed to uPAR, whether this interaction alone is critical to urokinase (uPA)- and uPAR-dependent signaling and tumor promotion is unclear. Here we report the functional consequences of point mutations of uPAR (H249A-D262A) that eliminate beta1 integrin interactions but maintain uPA binding, vitronectin attachment and association with alphaV integrins, caveolin and epidermal growth factor receptor. Disruption of uPAR interactions with beta1 integrins recapitulated previously reported findings with beta1-integrin-derived peptides that attenuated matrix-dependent ERK activation, MMP expression and in vitro migration by human lung adenocarcinoma cell lines. The uPAR mutant cells acquired enhanced capacity to adhere to vitronectin via uPAR-alphaVbeta5-integrin, rather than through the uPAR-alpha3beta1-integrin complex and they were unable to initiate uPA signaling to activate ERK, Akt or Stat1. In an orthotopic lung cancer model, uPAR mutant cells exhibited reduced tumor size compared with cells expressing wild-type uPAR. Taken together, the results indicate that uPAR-beta1-integrin interactions are essential to signals induced by integrin matrix ligands or uPA that support lung cancer cell invasion in vitro and progression in vivo.

摘要

尿激酶受体(uPAR)在肿瘤细胞侵袭时上调,且与肺癌患者的不良预后相关。尽管已将uPAR与整合素的顺式相互作用归因于此,但这种相互作用本身对于尿激酶(uPA)和uPAR依赖性信号传导以及肿瘤促进是否至关重要尚不清楚。在此,我们报告了uPAR(H249A-D262A)点突变的功能后果,这些突变消除了β1整合素相互作用,但保留了uPA结合、玻连蛋白附着以及与αV整合素、小窝蛋白和表皮生长因子受体的结合。uPAR与β1整合素相互作用的破坏重现了先前用β1整合素衍生肽报道的结果,即减弱了人肺腺癌细胞系的基质依赖性ERK激活、MMP表达和体外迁移。uPAR突变细胞通过uPAR-αVβ5整合素获得了增强的黏附于玻连蛋白的能力,而不是通过uPAR-α3β1整合素复合物,并且它们无法启动uPA信号来激活ERK、Akt或Stat1。在原位肺癌模型中,与表达野生型uPAR的细胞相比,uPAR突变细胞的肿瘤尺寸减小。综上所述,结果表明uPAR-β1整合素相互作用对于整合素基质配体或uPA诱导的信号至关重要,这些信号支持肺癌细胞的体外侵袭和体内进展。